- Market Realist•7 hours ago
GSK expects the revenues of its Vaccines segment to grow with the addition of meningitis vaccines from Novartis and the growing demand in European markets.
- Market Realist•9 hours ago
GlaxoSmithKline’s Pharmaceuticals segment has declined substantially in 2015 due to the divestment of its oncology business to Novartis (NVS) in March 2015.
After hours: 44.04-0.01 (-0.02%) as of 4:02 PM EDT
|Bid||44.03 x 7000|
|Ask||44.04 x 600|
|52wk Range||37.24 - 45.49|
|Day's Range||43.65 - 44.06|
|Avg Vol (3m)||3,474,355|
As of 4:02 PM EDT. Market closed.